Michael Møller

10.4k total citations · 1 hit paper
161 papers, 4.2k citations indexed

About

Michael Møller is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Michael Møller has authored 161 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pathology and Forensic Medicine, 48 papers in Oncology and 46 papers in Genetics. Recurrent topics in Michael Møller's work include Lymphoma Diagnosis and Treatment (74 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (30 papers). Michael Møller is often cited by papers focused on Lymphoma Diagnosis and Treatment (74 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (30 papers). Michael Møller collaborates with scholars based in Denmark, United States and Spain. Michael Møller's co-authors include Thomas Kielsgaard Kristensen, Hanne Vestergaard, Niels T. Pedersen, Bjarne Christensen, Ole Nielsen, Sigurd Broesby‐Olsen, Carsten Bindslev‐Jensen, Ken H. Young, Hans Carl Hasselbalch and Tina Green and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael Møller

155 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012 481 citations Ken H. Young, Carlo Visco et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Møller Denmark	34	1.6k	1.3k	1.0k	966	945	161	4.2k
Berthold Streubel Austria	45	2.8k 1.8×	1.9k 1.5×	1.5k 1.4×	1.7k 1.8×	945 1.0×	149	6.5k
Antonio Pinto Italy	40	2.3k 1.4×	2.2k 1.7×	1.1k 1.1×	1.3k 1.3×	1.6k 1.7×	239	5.6k
Karen Leroy France	38	2.1k 1.3×	2.0k 1.5×	591 0.6×	1.3k 1.4×	957 1.0×	126	4.8k
Catherine A. Billups United States	48	868 0.5×	1.8k 1.4×	754 0.7×	2.0k 2.0×	256 0.3×	165	6.0k
Jeremy S. Abramson United States	40	2.6k 1.6×	3.3k 2.5×	1.2k 1.1×	1.0k 1.0×	1.0k 1.1×	237	5.5k
M. D’Incan France	34	1.6k 1.0×	754 0.6×	708 0.7×	461 0.5×	820 0.9×	144	4.1k
Swee T. Tan New Zealand	39	546 0.3×	1.5k 1.2×	572 0.5×	1.6k 1.6×	369 0.4×	191	5.3k
Edward Fox United States	35	3.6k 2.2×	1.5k 1.2×	181 0.2×	736 0.8×	1.2k 1.3×	156	6.0k
A. Z. S. Rohatiner United Kingdom	43	4.2k 2.6×	3.1k 2.4×	2.1k 2.0×	854 0.9×	945 1.0×	117	6.8k
Lucienne Michaux Belgium	38	1.4k 0.9×	1.1k 0.8×	1.3k 1.3×	1.3k 1.3×	982 1.0×	184	4.5k

Countries citing papers authored by Michael Møller

Since Specialization

Citations

This map shows the geographic impact of Michael Møller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Møller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Møller more than expected).

Fields of papers citing papers by Michael Møller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Møller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Møller. The network helps show where Michael Møller may publish in the future.

Co-authorship network of co-authors of Michael Møller

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Møller. A scholar is included among the top collaborators of Michael Møller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Møller. Michael Møller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cédile, Oriane, Mads Thomassen, Michael Møller, et al.. (2025). Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non‐Hodgkin Large B‐Cell Lymphoma: A Comparative Study of Cell‐Free DNA and Formalin‐Fixed Paraffin‐Embedded Tissue. International Journal of Laboratory Hematology. 47(4). 669–679. 1 indexed citations

Grantzau, Trine, Mia Dahl Sørensen, Michael Møller, et al.. (2025). Reduced CD20 expression yields inferior survival in patients with B-cell lymphoma treated with CD20×CD3 antibodies. PubMed. 2(3). 100096–100096.

Brændstrup, Peter, Tarec Christoffer El‐Galaly, Michael Møller, et al.. (2024). Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022. Blood. 144(Supplement 1). 3099–3099.

Cédile, Oriane, Jakub Krejcik, Niels Abildgaard, et al.. (2024). Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 25(23). 12569–12569.

Christoffersen, Mette, Hanne Lindegaard, Jesper Rømhild Davidsen, et al.. (2023). The multidisciplinary approach to eosinophilia. Frontiers in Oncology. 13. 1193730–1193730. 13 indexed citations

Gerke, Oke, et al.. (2023). A retrospective head‐to‐head comparison of the Lugano classification and PERCIST for FDG‐PET/CT response assessment in diffuse large B‐cell lymphoma. Clinical Physiology and Functional Imaging. 44(1). 70–78. 3 indexed citations

Saliba, Rima M., Uri Greenbaum, Qing Ma, et al.. (2021). Mismatch in SIRPα, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Advances. 5(17). 3407–3417. 5 indexed citations

Plesner, Trine Lindhardt, Martin Bjerregård Pedersen, Maja Ludvigsen, et al.. (2017). Lympho- and Myeloproliferative Malignancies Occurring in the Same Host: Description of a Nationwide Discovery Cohort. 1 indexed citations

Kristensen, Thomas Kielsgaard, Niels Abildgaard, Mads Thomassen, et al.. (2015). High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia. Leukemia Research. 39(6). 555–560. 16 indexed citations

10.

Frei, Emil, Carlo Visco, Zijun Y. Xu‐Monette, et al.. (2013). Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma. Journal of Clinical Pathology. 66(11). 956–961. 19 indexed citations

11.

Sun, Peng, Nitin Mantri, Michael Møller, et al.. (2012). Influence of light and salt on the growth of alien invasive tropical weed Ageratum conyzoides. Australian Journal of Crop Science. 6(4). 739–748. 3 indexed citations

12.

Kristensen, Thomas Kielsgaard, Michael Møller, Lone Smidstrup Friis, Olav J. Bergmann, & Birgitte Preiss. (2011). NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*. European Journal Of Haematology. 87(5). 400–408. 34 indexed citations

13.

Brown, Peter de Nully, Lars Møller Pedersen, Bjarne Bach Pedersen, et al.. (2008). Follicular lymphoma in young patients (>50 yrs): A population-based analysis of the Danish lymphoma registry. Annals of Oncology. 19. 176–176. 4 indexed citations

14.

d’Amore, Francesco, Peter de Nully Brown, Lars Møller Pedersen, et al.. (2008). Primary refractory disease in non-Hodgkin lymphoma (NHL): Occurence, clinico-pathological features, and outcome. Annals of Oncology. 19. 132–132. 1 indexed citations

15.

Sjø, Lene Dissing, Christian Bjørn Poulsen, Mads Hansen, Michael Møller, & Elisabeth Ralfkiær. (2007). Profiling of diffuse large B‐cell lymphoma by immunohistochemistry: identification of prognostic subgroups. European Journal Of Haematology. 79(6). 501–507. 42 indexed citations

16.

Larsen, Thomas Stauffer, Niels Pallisgaard, Jacob Haaber Christensen, et al.. (2006). Nye molekylære markører ved de kroniske myeloproliferative sygdomme. I: PRV1-genet. Ugeskrift for Læger. 168(39). 3295–3299. 1 indexed citations

17.

Møller, Michael, et al.. (2006). Naturschutz ernst genommen – europarechtlich geforderte Reformen des deutschen Naturschutzrechts. 4(4). 8.

18.

Møller, Michael, Karsten Skjødt, Leif Spange Mortensen, & Niels T. Pedersen. (1999). Clinical significance of cyclin‐dependent kinase inhibitor p27^Kip1 expression and proliferation in non‐Hodgkin's lymphoma: independent prognostic value of p27^Kip1. British Journal of Haematology. 105(3). 730–736. 23 indexed citations

19.

Møller, Michael & Niels Chr. Nielsen. (1993). Pensionsopsparing og statsgæld. Nationaløkonomisk tidsskrift. 131. 1 indexed citations

20.

Møller, Michael, et al.. (1992). Anschluß verpaßt : Armut in Deutschland. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact